Last Updated: September 24, 2026

CYTADREN Drug Patent Profile

Name: CYTADREN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Cytadren patents expire, and when can generic versions of Cytadren launch?

Cytadren is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in CYTADREN is aminoglutethimide. There is one drug master file entry for this compound. Additional details are available on the aminoglutethimide profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CYTADREN?
What are the global sales for CYTADREN?
What is Average Wholesale Price for CYTADREN?

Summary for CYTADREN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	1,891
DailyMed Link:	CYTADREN at DailyMed

Drug patent expirations by year for CYTADREN

Recent Clinical Trials for CYTADREN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
H. Lee Moffitt Cancer Center and Research Institute	Phase 2
National Cancer Institute (NCI)	Phase 2
Janssen Pharmaceuticals	Phase 2

See all CYTADREN clinical trials

US Patents and Regulatory Information for CYTADREN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	CYTADREN	aminoglutethimide	TABLET;ORAL	018202-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CYTADREN

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	CYTADREN	aminoglutethimide	TABLET;ORAL	018202-001	Approved Prior to Jan 1, 1982	3,595,960	⤷ Start Trial
Novartis	CYTADREN	aminoglutethimide	TABLET;ORAL	018202-001	Approved Prior to Jan 1, 1982	3,944,671	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.